Four challenges for Pulmonary Drug Delivery
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis are among the most serious and widespread healthcare challenges facing the developed world, accounting for more than 400,000 deaths in the European Union, equivalent to 8% of the total mortality figure. Such figures highlight the growing need for innovative and effective treatments.
Pulmonary drug delivery is receiving increased attention as a non-invasive means for local treatment of a wide range of major lung diseases; this route of administration, however, poses a number of additional challenges for medicinal and formulation chemists.
This article reviews the issues specific to developing drugs designed for pulmonary delivery and considers how - with the right knowledge and expertise - these challenges can be overcome.